Tag
NASDAQ: TEM
- Guardant Health adds five epigenomic tools for cancer treatment selection
- SOPHiA GENETICS reports 25% revenue growth and holds sales range
- Tempus AI receives European IVDR certification for xR cancer profiling
- NeoGenomics expands Indica Labs partnership for digital pathology
- Guardant Health gains European CE mark for ESR1 breast cancer test
- Novocure receives Japanese approval for Optune Pax pancreatic cancer device
- Tempus AI wins FDA clearance for fourth ECG tool targeting mitral regurgitation
- Tempus AI buys Personalis to strengthen AI‑driven cancer monitoring platform
- Cambridge researchers develop urine test that could detect lung cancer years earlier
- Eli Lilly inks USD$2.75B AI drug deal with Insilico Medicine
- Tempus AI, Daiichi Sankyo team up to boost cancer drug trials with AI
- Mark Zuckerberg backs AI‑biology project to predict, prevent, and treat disease
- The promises and perils of artificial intelligence: a Mugglehead roundup
- Alibaba Group gets FDA nod for cancer detection tool
- Personalis Inc share price jumps 50% on deals with Merck and Moderna